Ryoncil® Profits Underpinning Substantial Growth Pipeline

Year Ended December 31, 2025NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today ...